LayerBio to Present Preclinical Results for Extended Release Glaucoma

Formulation at ARVO

LayerBio will present preclinical study results at the Association for Research in Vision and
Ophthalmology in Honolulu, Hawaii on Monday, April 30. These results demonstrate the
therapeutic potential of its novel extended-release travoprost formulation using LayerBio's
proprietary PolyNet™ delivery technology.

Honolulu, HI, April 27, 2018 --(PR.com)-- LayerBio will present preclinical study results at the
Association for Research in Vision and Ophthalmology in Honolulu, Hawaii on Monday, April 30.

In this study, LayerBio's proprietary intracameral extended-release formulation of the glaucoma drug
travoprost is shown to lower intraocular pressure to therapeutic levels for longer than six months.

"Implantable extended release formulations are an emerging class of treatments for glaucoma.
Conventional eye drops are often ineffective due to lack of patient compliance with their prescribed
regimens," explains Dr. Ken Mandell, LayerBio's CEO. "Furthermore, sustained-release formulations
afford 24-hour drug coverage, a distinct advantage over eye drops."

LayerBio's extended-release travoprost formulation is based on its PolyNet™ technology, a proprietary

network polymer-based delivery platform invented by Dr. Mandell at LayerBio. PolyNet™ enables
tunable control of drug release from a biocompatible, bio-erodible polymer system with a variety of
classes of medications for glaucoma and other ophthalmic indications.

"The results presented at ARVO demonstrate the therapeutic advantages of our travoprost formulation
and the PolyNet™ platform," commented Dr. Paula Hammond, co-founder of LayerBio and Head of
Chemical Engineering at MIT. "LayerBio's technology has the potential to improve the way we treat eye
disease."

Page 1/2
PR.com Press Release Distribution Terms of Use
Contact Information:
LayerBio, Inc.
Ken Mandell
617-453-8210
Contact via Email
www.layerbio.com

Online Version of Press Release:

You can read the online version of this press release at: https://www.pr.com/press-release/752149

Page 2/2
PR.com Press Release Distribution Terms of Use